RhumbLine Advisers
RARX

RhumbLine Advisers’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

RhumbLine Advisers’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-50,313
Closed -$2.42M – 3192
2020
Q1 		$2.42M Buy
50,313
+2,767
+6% +$129K 0.01% 1447
2019
Q4 		$2.23M Buy
47,546
+6,749
+17% +$298K ﹤0.01% 1744
2019
Q3 		$965K Buy
40,797
+2,712
+7% +$80.4K ﹤0.01% 2045
2019
Q2 		$1.15M Buy
38,085
+12,400
+48% +$284K ﹤0.01% 2003
2019
Q1 		$575K Buy
25,685
+4,960
+24% +$107K ﹤0.01% 2269
2018
Q4 		$377K Buy
20,725
+6,432
+45% +$101K ﹤0.01% 2429
2018
Q3 		$259K Buy
14,293
+164
+1% +$1.94K ﹤0.01% 2594
2018
Q2 		$141K Buy
14,129
+1,900
+16% +$13.1K ﹤0.01% 2826
2018
Q1 		$65K Buy
12,229
+1,490
+14% +$10.6K ﹤0.01% 2785
2017
Q4 		$91K Sell
10,739
-2,280
-18% -$28K ﹤0.01% 2787
2017
Q3 		$190K Buy
13,019
+185
+1% +$2.8K ﹤0.01% 2757
2017
Q2 		$241K Buy
+12,834
New +$290K ﹤0.01% 2665

Other funds holding RARX

Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

RhumbLine Advisers's RARX Position: Q2 2020 in Review

RhumbLine Advisers sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 50,313 shares — an estimated $2.42M sold.

RhumbLine Advisers first reported a position in RARX in Q2 2017 and held it in 12 quarters. The position peaked at $2.42M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

  • RhumbLine Advisers reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • RhumbLine Advisers sold 50,313 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $2.42M.
  • RhumbLine Advisers first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 12 quarters.
  • RhumbLine Advisers's Ra Pharmaceuticals, Inc. Common Stock position peaked at $2.42M in Q1 2020.
  • 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on RhumbLine Advisers's 13F filing for Q2 2020, filed 13 Aug 2020.